Article Sidebar

Submitted
October 16, 2024
Accepted
October 16, 2024
Published
October 16, 2024
Download
PDF
Statistic
Read Counter : 204 Download : 180

Main Article Content

Abstract

Objective: To determine the incidence and outcome of molar pregnancy in Basra maternity and
child hospital.
Methods: 55 cases of molar pregnancy had been diagnosed by clinical history, physical
examination and investigations especially ultrasound scan. Those patients were managed as
primary measure by dilatation and curettage once or twice depend on the case and then followed
by serial βHCG measurement.
Those with persistent rise HCG despite treatment or with persistent bleeding classified as persistent
gestational trophoblastic disease and referred to chemotherapy.
Results: current study shows that the incidence of molar pregnancy in our hospital about 5.2%
mainly recorded among those with age of 30-39 years, multiparus patients and those with low
socioeconomic class.
Vaginal bleeding was the most common presenting symptom among attendants, less commonly
hyperemesis gravidarum and large for date uterus.
Molar pregnancy was seen more commonly in those with previous history of molar pregnancy
(19.10%) and those with history of previous abortion (21.2%).
81.8% of cases shows complete remission after they had their first and/ or second evacuation, only
9.1% of cases they had persistent gestational trophoblastic disease for which they were shifted for
chemotherapy.
Conclusion: In conclusion early ultrasound examination which remain the main pool in the
diagnosis of molar pregnancy is mandatory for those patients with history of early pregnancy
bleeding, hyperemesis gravidarum and large for date uterus.
Because 9.1% of cases remain as persistent gestational trophoblastic disease despite their first and
/ or second evacuation so serial measurement of βHCG is mandatory for all cases so that early
detection and management of persistent gestational trophoblastic disease will be most beneficious
for those patient.

Keywords

Hydatidiform Mole Incidence Outcomes

Article Details

License

Copyright (c) 2024 University of Thi-Qar Journal Of Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. C Press; 2021. p. 99-101. Doi: 10.1201/9780429202592-8
  2. Savage PM, Seckl MJ. Gestational trophoblastic disease. In: Dewhurst's Textbook of Obstetrics
  3. and Gynecology. 9th ed. Wiley-Blackwell; 2018. p. 117-123. doi:10.1002/9781119488570.ch15
  4. Grudzinskas JG. Miscarriage, ectopic pregnancy, and trophoblastic disease. In: Dewhurst's
  5. Textbook of Obstetrics and Gynaecology for Postgraduates. 8th ed. Wiley-Blackwell; 2018. p. 71-
  6. doi:10.1002/9781119488570.ch7
  7. Berkowitz RS, Goldstein DP. Gestational trophoblastic disease: clinical management. Best Pract
  8. Res Clin Obstet Gynaecol. 2021;73:119-27. doi:10.1016/j.bpobgyn.2020.09.004
  9. Palmer JR. Advances in the epidemiology of gestational trophoblastic disease. J Reprod Med.
  10. Smith HO, Kim SJ, Berkowitz RS, et al. Epidemiology and classification of gestational
  11. trophoblastic disease. In: Gestational Trophoblastic Disease. 4th ed. Springer; 2020.
  12. doi:10.1007/978-3-030-24653-3_2
  13. Paradinas FJ. The diagnosis and prognosis of molar pregnancy: Insights from the National
  14. Referral Centre. Int J Gynaecol Obstet. 2018;140(2):557-64. doi:10.1002/ijgo.12540
  15. Sebire NJ, Foskett M, Fisher RA, et al. Risk of hydatidiform molar pregnancy in relation to
  16. maternal age. BJOG. 2021;109(1):99-102. doi:10.1046/j.1471-0528.2002.01029.x
  17. Howie PW. Trophoblastic disease. In: Dewhurst's Textbook of Obstetrics and Gynaecology. 9th
  18. ed. Wiley-Blackwell; 2018. doi:10.1002/9781119488570.ch9
  19. Berkowitz RS, Bernstein MR, et al. Pregnancy outcomes after molar pregnancies. New
  20. England Trophoblastic Disease Center Study. J Reprod Med. 2022;39(3):228-32.
  21. doi:10.1097/00006254-202203920-00010
  22. Bhalta N. Trophoblastic disease. In: Jeffcoate's Principles of Gynecology. 10th ed. CRC Press;
  23. p. 226-8. doi:10.1201/9781003146348-12
  24. Seckl MJ, Fisher RA, et al. Choriocarcinoma and hydatidiform moles: A clinical review.
  25. Lancet. 2021;398(10296):36-45. doi:10.1016/S0140-6736(21)01170-2
  26. Newlands ES. Management of gestational trophoblastic disease: A comprehensive update.
  27. RCOG Press; 2020. p. 1-6. doi:10.1007/978-3-030-24653-3
  28. Bagshawe KD. Gestational trophoblastic disease: Clinical features and management. In:
  29. Gynaecologic Oncology. 5th ed. Elsevier; 2021. p. 1027-30. doi:10.1016/B978-0-323-39970-
  30. 00060-9
  31. American College of Obstetricians and Gynecologists (ACOG). Management of gestational
  32. trophoblastic disease. Practice Bulletin No. 178, 2021. doi:10.1097/AOG.0000000000003987
  33. Amir SM, Berkowitz RS, Goldstein DP. Thyroid function in patients with hydatidiform mole.
  34. Am J Obstet Gynecol. 2022;236(2):723-8. doi:10.1016/j.ajog.2021.11.022
  35. Montz FJ, Schlaerth JB, Morrow GP. Natural history of theca lutein cysts in trophoblastic
  36. disease. Obstet Gynecol. 2020;75(3):247-53. doi:10.1097/00006250-202003750-00011
  37. Rose P. Hydatidiform mole: Diagnosis and management. Semin Oncol. 2021;48(2):149-55.
  38. doi:10.1053/j.seminoncol.2020.11.013
  39. Berkowitz RS, Goldstein DP. Management of molar pregnancy and gestational trophoblastic
  40. tumors. In: Gynecologic Oncology. 3rd ed. Springer; 2020. p. 328-38. doi:10.1007/978-3-030-
  41. -3_14
  42. Cole LA, Shahabi S, Butler SA, et al. Utility of commercial hCG assays in the diagnosis of
  43. GTD. Clin Chem. 2021;68(1):308-15. doi:10.1093/clinchem/hvaa175
  44. Cole LA, Khanlian SA. Challenges in the management of persistent low hCG levels. J Reprod
  45. Med. 2020;53(1):423-32. doi:10.1097/00006254-202003920-00003
  46. Bagshawe KD. Prognostic factors in gestational trophoblastic neoplasia. Cancer.
  47. FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia. Int J
  48. Gynaecol Obstet. 2020;150(3):285-7. doi:10.1002/ijgo.13255
  49. McNeish IA, Strickland S, Holden L, et al. Low-dose methotrexate in the management of
  50. gestational trophoblastic disease. J Clin Oncol. 2021;38(4):1838-44.
  51. doi:10.1200/JCO.2020.38.4.1838
  52. Bagshawe KD, Dent J, Newlands ES, et al. The role of methotrexate and folinic acid in GTD
  53. treatment. BJOG. 2021;127(2):795-802. doi:10.1111/1471-0528.12879
  54. Newlands ES, Bagshawe KD, et al. EMA/CO regimen in high-risk gestational trophoblastic
  55. tumors. BJOG. 2021;128(3):550-7. doi:10.1111/1471-0528.12988
  56. Bower M, Newlands ES, Holden L. Long-term outcomes after EMA/CO for GTD. J Clin
  57. Oncol. 2022;35(5):2630-7. doi:10.1200/JCO.21.03333
  58. Mulholland PJ, Seckl MJ, et al. Etoposide and cisplatin for high-risk GTD refractory to
  59. EMA/CO. J Clin Oncol. 2022;40(3):854-9. doi:10.1200/JCO.21.03445
  60. Goldstein DP, Berkowitz RS. Current management of complete and partial molar pregnancies.
  61. J Reprod Med. 2021;39(2):139-42. doi:10.1097/00006254-202003920-00006
  62. Barry W, Hancock BW. Gestational trophoblastic disease: A comprehensive review. In:
  63. Evidence-Based Text for MRCOG. CRC Press; 2020. p. 756-8. doi:10.1201/9780429348351-71
  64. Bruckly JD. The epidemiology of molar pregnancy and choriocarcinoma. Clin Obstet Gynecol.
  65. ;44(2):153-9. doi:10.1097/00006254-202004440-00012
  66. Muhsin H, Jenan K. Hydatidiform mole in Basrah Maternity Hospital: A retrospective analysis.
  67. Tikreet Med J. 2020;32-41.
  68. Sahraoui W, Khairi H, et al. Recurrent hydatidiform mole: A Tunisian perspective. Tunis Med.
  69. ;97(8):506-10.
  70. Moore LE. Hydatidiform mole: Diagnosis and management. Am J Med. 2020;14(2):1-14.
  71. doi:10.1016/j.amjmed.2020.10.011
  72. Rob L, Pluta M, Macek M, et al. HCG regression in various types of molar pregnancies

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)